Cynvenio Research Highlights Need for Longitudinal Monitoring of Triple Negative Breast Cancer Patients

The preliminary data shows the importance of a multi-template approach to provide greater visibility on a patient’s tumor landscape and the ultimate value of longitudinal monitoring to track persistent mutations.

Cynvenio Biosystems, Inc. a leader in personalized medicine technology for cancer diagnostics, announced the company will present preliminary data to support the utility of longitudinal monitoring of triple negative breast cancer patients using Cynvenio’s ClearID liquid biopsy tests. These data were collected during the first year of Cynvenio’s clinical research study, “A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women with Previously Treated Non-metastatic Triple Negative Breast Cancer and Women with Previously Treated Non-metastatic Breast Cancer With a confirmed BRCA Mutation” (clinicaltrials.gov identifier NCT02639832).

This ongoing study, which launched in December 2015, examines the utility of serial liquid biopsies using a multi-template approach that identifies and analyzes cell-free DNA (cfDNA), circulating tumor cells (CTCs), and germline DNA (gDNA). Enrolled in the study are 211 women with a confirmed diagnosis of Triple Negative Breast Cancer (TNBC), who were within three years of completion of therapy when they entered the study and had no evidence of residual/recurrent cancer. On average, each participant has had four serial samples collected to date which have been analyzed using Cynvenio’s ClearID® Breast Cancer custom 27-oncogene panel.

The data collected shows the majority of participants have had evidence of genomic mutations in at least one sample, but did not show these changes in consecutive blood draws and have not experienced documented recurrence. In…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *